PenMetabolic · NNMT inhibitor
5-Amino-1MQ 25 mg
A selective NNMT inhibitor studied for fat-mass reduction and NAD⁺ research.
View 25 mg
FOX04-DRI PENLongevity · Senolytic
FOX04-DRI 10 mg
Strength 10 mg / 3 mLPurity HPLCForm Pre-filled penCOA Per batch
A senolytic research peptide that disrupts the FOXO4–p53 interaction, studied for the selective clearance of senescent cells in ageing-research models, here as a ready-to-use pen.
Researched directions
- FOXO4–p53 disruption research
- Selective senescent-cell (senolytic) clearance
- Tissue-ageing and regeneration models
- Cellular-stress and p53-pathway endpoints
Available to verified researchers. Pricing and the batch Certificate of Analysis are shared on request.
About FOX04-DRI
FOX04-DRI is a senolytic peptide studied for disrupting the FOXO4–p53 interaction, prompting apoptosis in senescent cells while sparing healthy ones. This 10 mg pen supports repeat-dose ageing-research designs.
Features
FOX04-DRI is supplied in the NADOVA LABS GoQuick pre-filled pen — a graduated, ready-to-use subcutaneous delivery format that removes reconstitution and simplifies repeat-dose study designs. Each pen is prepared from HPLC-verified material, dose-marked on the barrel, and shipped refrigerated with a Certificate of Analysis available per batch.
Handling & compliance
This pre-filled pen is intended strictly for in-vitro and laboratory research. It is not a drug, supplement, or medical device, and is not for human use. Store refrigerated at 2–8 °C, protect from light, and follow accepted laboratory practice; exact specifications for your lot are listed on its Certificate of Analysis.
Related compounds
Back to catalogue Pen
PenLongevity · NAD⁺
NAD+ 1000 mg
The NAD⁺ coenzyme studied for cellular energy, DNA repair and longevity research.
View 1000 mg
Every batch, documented.
Request a researcher account to view the Certificate of Analysis for this lot and place an order with the lab.